Celanese Corp (CE) reported an equity award to a senior executive. A Form 4 filing shows that an officer serving as SVP & General Counsel received 6,624 shares of Celanese common stock on 11/17/2025 in the form of time-based restricted stock units granted under the company’s Amended and Restated 2018 Global Incentive Plan. The award was recorded at a price of $0 per share, reflecting that it is a compensatory grant rather than an open-market purchase.
Each RSU represents the right to receive one share of common stock, with vesting subject to continued employment. The RSUs will vest 50% on November 17, 2026 and the remaining 50% on November 17, 2027. After this grant, the reporting person directly beneficially owned 20,459 shares, and an additional 624.623 shares were held indirectly through a 401(k) plan.
Celanese Corp (CE) director Kim K.W. Rucker filed a Form 4 reporting the acquisition of 7.29 shares of phantom stock on 11/12/2025, coded “A.” The filing lists a price of $39.12 for the derivative security.
Each phantom share represents the right to receive one share of common stock, with payment in stock under the company’s 2008 Deferred Compensation Plan after the director’s service ends. Following the transaction, 9,514.09 derivative securities were beneficially owned directly.
Celanese Corp (CE) director Deborah J. Kissire reported an acquisition of derivative securities on a Form 4. On 11/12/2025, she acquired 4.54 units of phantom stock (Transaction Code A) at a price of $39.12 per the derivative security entry.
Each phantom stock unit represents the right to receive one share of Common Stock. Following the transaction, she beneficially owned 5,921.288 derivative securities directly. The phantom stock relates to dividend equivalents under the company’s 2008 Deferred Compensation Plan and becomes payable in shares after her service as a director ends.
Celanese (CE) director Jay V. Ihlenfeld filed a Form 4 reporting an acquisition of 7.84 shares of phantom stock on 11/12/2025 (Code A). Following this transaction, he beneficially owns 10,235.059 derivative securities, held directly.
Each phantom share represents the right to receive one share of common stock. The reported phantom stock reflects dividend equivalents on compensation deferred under the company’s 2008 Deferred Compensation Plan and becomes payable in common shares after the director’s service ends, as provided in the plan.
Celanese Corp (CE) reported a Form 4 for director Kathryn Hill. On 11/12/2025, she acquired 2.26 units of phantom stock (transaction code A) at a derivative price of $39.12. After this transaction, she beneficially owned 2,948.87 derivative securities directly.
Each phantom stock unit represents the right to receive one share of common stock. The reported phantom stock reflects dividend equivalents on compensation deferred under the company’s 2008 Deferred Compensation Plan and becomes payable in shares of common stock following the end of her service as a director.
Celanese Corporation (CE) director Timothy Go reported an acquisition of 0.86 phantom stock units on 11/12/2025 (Transaction Code: A). Each phantom stock unit represents the right to receive one share of common stock.
The units reflect dividend equivalents credited under the company’s 2008 Deferred Compensation Plan and become payable in common stock following the end of his service as a director. After this transaction, his directly held derivative securities balance is 1,115.57 units.
Celanese (CE) director Edward G. Galante reported an acquisition of 5.21 phantom stock units on 11/12/2025 under a Form 4 filing. Following this transaction, he beneficially owns 6,802.765 derivative securities.
The transaction was coded A (acquired). Each phantom stock unit represents the right to receive one share of common stock. The reported phantom stock reflects dividend equivalents on compensation deferred under the Company’s 2008 Deferred Compensation Plan and becomes payable in shares of common stock after his service as a director ends. The filing lists a Price of Derivative Security of $39.12.
Celanese Corporation (CE) reported a large GAAP loss driven by non‑cash impairments. For Q3 2025, net sales were $2,419 million and net loss was $1,353 million as Other (charges) gains, net totaled $1,491 million. Operating loss was $1,275 million. Year‑to‑date, net sales were $7,340 million with a net loss of $1,173 million.
The quarter included a goodwill impairment of about $1.0 billion in Engineered Materials, an additional $98 million linked to the Micromax® held‑for‑sale classification, and a $346 million impairment of certain trade names. Cash from operations rose to $894 million for the nine months, lifting cash to $1,440 million and shareholders’ equity to $3,954 million. The company signed an agreement on October 28, 2025 to divest its Micromax® portfolio to Element Solutions for approximately $500 million in cash, subject to adjustments and approvals. Celanese also announced plans to close its Lanaken, Belgium facility, expecting $70–$90 million of exit and shutdown costs during 2026–2028.
Debt stood at $11,655 million long‑term (net), with March 2025 note issuances of $700 million (2030, 6.500%), €750 million (2031, 5.000%) and $1,100 million (2033, 6.750%), alongside tender offers for €552 million (2026) and $500 million (2027) notes.
Celanese Corporation announced a Regulation FD webcast for investors and analysts on November 7, 2025 at 9:00 a.m. ET to discuss its third quarter 2025 results. CEO Scott A. Richardson will present, with materials available at investors.celanese.com under News & Events.
The company furnished exhibits including prepared remarks and a slide presentation (Exhibits 99.1(a) and 99.1(b)). Non‑US GAAP measures referenced in the remarks are defined and reconciled to the most comparable US GAAP metrics in Exhibit 99.2. These materials are furnished, not filed.
Celanese Corporation (CE) furnished an 8-K announcing it issued a press release reporting financial results for the third quarter of 2025. The press release is provided as Exhibit 99.1.
Non‑US GAAP measures referenced in the release are reconciled to the most comparable US GAAP measures in Exhibit 99.2. The information was furnished under Item 2.02 and is not deemed filed under the Exchange Act.